Cogent Biosciences Inc

COGT

37.080USD

+1.380+3.87%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Cogent Biosciences Inc's Score

Industry at a Glance

Industry Ranking

92 / 392

Overall Ranking

219 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Cogent Biosciences Inc Highlights

StrengthsRisks

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -19.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 160.57M shares, increasing 0.02% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 304.58K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.34.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

50.667

Target Price

+41.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cogent Biosciences Inc is 6.80, ranking 211 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cogent Biosciences Inc is 6.32, ranking 297 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.07, which is -89.34% below the recent high of -2.03 and -13.57% above the recent low of -21.65.

Score

Industry at a Glance

Previous score

6.32

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cogent Biosciences Inc is 8.62, ranking 91 out of 392 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 65.00 and a low of 34.00.

Score

Industry at a Glance

Previous score

8.62

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cogent Biosciences Inc is 7.34, ranking 79 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 41.01 and the support level at 33.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.03

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cogent Biosciences Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.91%, representing a quarter-over-quarter decrease of 24.93%. The largest institutional shareholder is The Vanguard, holding a total of 11.49M shares, representing 6.56% of shares outstanding, with 23.57% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

20.66M

+29.60%

The Vanguard Group, Inc.

Star Investors

7.73M

+18.87%

BlackRock Institutional Trust Company, N.A.

9.33M

+20.24%

Deerfield Management Company, L.P.

9.05M

--

Kynam Capital Management LP

7.89M

-7.14%

Commodore Capital LP

7.25M

+110.14%

TCG Crossover Management, LLC

6.80M

-2.39%

Fairmount Funds Management LLC

9.00M

--

State Street Investment Management (US)

4.78M

+41.62%

VR Adviser, LLC

4.00M

-15.89%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cogent Biosciences Inc is 1.88, ranking 275 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Cogent Biosciences Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Cogent Biosciences Inc

COGT

6.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment